MedDataX Logo

Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients

NCT ID: NCT01022450

Last Updated: 2009-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Analyze the various causes of breakdown of muscle fibers in hospitalized patients.
2. Analyze the characteristics of these patients in Taiwan (including the drugs history, risk factors and the incidence of complications).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Find the causes of breakdown of muscle fibers in hospitalized patients through medical record review.

* especially drug-related
2. Find the risk factors of muscle fibers breakdown.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhabdomyolysis Myopathy Acute Renal Failure Neuroleptic Malignant Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

rhabdomyolysis myopathy acute renal failure neuroleptic malignant syndrome Pharmaceutical Preparations Hydroxymethylglutaryl-CoA Reductase Inhibitors fibrates creatine kinase

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who admitted to The National Taiwan University Hospital during 2003/1/1\~2008/12/31 with the following discharge diagnosis: myoglobinuria, rhabdomyolysis, myopathy, toxic myopathy, malignant hyperthermia, neuroleptic malignant syndrome, polymyositis, myalgia and had acute neuromuscular illness presentations and serum creatinine kinase (CK) more than 5 times the upper limit of normal (male \> 900 IU/L; female \> 835 IU/L).

Exclusion Criteria

* Patients with recent myocardial infarction or stroke, unless clinical history, examination, or electromyography showed a concomitant myopathy.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fe-Lin L Wu, MSCP, PhD

Role: PRINCIPAL_INVESTIGATOR

Graduate Institute of Clinical Pharmacy, National Taiwan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Taiwan University Hospital

Taipei, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fe-Lin L Wu, MSCP, PhD

Role: CONTACT

Phone: +886-2-23123456

Email: [email protected]

Kwan-Dun Wu, MD, PhD

Role: CONTACT

Phone: +886-2-23123456

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kwan-Dun Wu, MD, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

200911033R

Identifier Type: -

Identifier Source: org_study_id